

Mukta Arora

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2089462/publications.pdf>

Version: 2024-02-01

160
papers

7,632
citations

136885

32
h-index

58549

82
g-index

161
all docs

161
docs citations

161
times ranked

7014
citing authors

#	ARTICLE	IF	CITATIONS
1	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 389-401.e1.	2.0	2,636
2	Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2015, 125, 1333-1338.	0.6	395
3	Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e177-e182.	2.0	378
4	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. <i>Blood</i> , 2017, 130, 2243-2250.	0.6	352
5	Increasing Incidence of Chronic Graft-versus-Host Disease in Allogeneic Transplantation: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 266-274.	2.0	331
6	Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. <i>Blood</i> , 2011, 118, 4242-4249.	0.6	196
7	A Refined Risk Score for Acute Graft-versus-Host Disease that Predicts Response to Initial Therapy, Survival, and Transplant-Related Mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 761-767.	2.0	195
8	Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). <i>Blood</i> , 2011, 118, 1413-1420.	0.6	176
9	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009, 113, 5074-5082.	0.6	143
10	Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 265-273.	2.0	130
11	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011, 117, 6714-6720.	0.6	128
12	Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study. <i>Blood</i> , 2021, 138, 2278-2289.	0.6	124
13	Biomarker Panel for Chronic Graft-Versus-Host Disease. <i>Journal of Clinical Oncology</i> , 2016, 34, 2583-2590.	0.8	118
14	Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 449-455.	2.0	113
15	HLA-Identical Sibling Compared With 8/8 Matched and Mismatched Unrelated Donor Bone Marrow Transplant for Chronic Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1644-1652.	0.8	100
16	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 2020-2028.	3.2	98
17	Physiologic Frailty in Nonelderly Hematopoietic Cell Transplantation Patients. <i>JAMA Oncology</i> , 2016, 2, 1277.	3.4	93
18	HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282.	0.6	88

#	ARTICLE	IF	CITATIONS
19	Chronic graft-versus-host disease: A prospective cohort study. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 38-45.	2.0	81
20	Improved survival after acute graft- <i>versus</i> -host disease diagnosis in the modern era. <i>Haematologica</i> , 2017, 102, 958-966.	1.7	79
21	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2002-2007.	2.0	64
22	Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB). <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1145-1152.	2.0	59
23	An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 360-367.	0.6	52
24	Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2004, 10, 395-404.	2.0	48
25	Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes. <i>Blood Advances</i> , 2020, 4, 2810-2820.	2.5	47
26	Machine learning reveals chronic graft- <i>versus</i> -host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies. <i>Haematologica</i> , 2019, 104, 189-196.	1.7	44
27	Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors. <i>Blood</i> , 2016, 128, 2350-2358.	0.6	43
28	Impact of Psychological Distress on Quality of Life, Functional Status, and Survival in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2285-2292.	2.0	38
29	Hematopoietic Cell Transplantation with Cryopreserved Grafts for Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e161-e166.	2.0	38
30	Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. <i>Journal of Clinical Oncology</i> , 2020, 38, 2062-2076.	0.8	36
31	Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium. <i>Blood Advances</i> , 2021, 5, 4278-4284.	2.5	36
32	Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 926-933.	2.0	35
33	Comparative Analysis of Calcineurin Inhibitor-â€‘Based Methotrexate and Mycophenolate Mofetil-â€‘Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 73-85.	2.0	35
34	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1459-1468.	2.0	35
35	Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 967-972.	2.0	34
36	Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 521-528.	2.0	34

#	ARTICLE	IF	CITATIONS
37	A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801. <i>Haematologica</i> , 2018, 103, 1915-1924.	1.7	34
38	Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades. <i>JAMA Oncology</i> , 2021, 7, 1626.	3.4	33
39	Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 390-393.	2.0	28
40	Sirolimus and Mycophenolate Mofetil as Calcineurin Inhibitor-Free Graft-versus-Host Disease Prophylaxis for Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2025-2030.	2.0	27
41	Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802. <i>Blood Advances</i> , 2018, 2, 1882-1888.	2.5	27
42	Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood. <i>JAMA Oncology</i> , 2018, 4, e182453.	3.4	27
43	Hematopoietic Cell Transplantation-Related Toxicities and Mortality in Frail Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2454-2460.	2.0	27
44	Physiologic Frailty Among Hematopoietic Cell Transplantation (HCT) Survivors Suggests Accelerated Aging and Is a Predictor for Premature Mortality: A Report from the Bone Marrow Transplant Survivor Study (BMTSS). <i>Blood</i> , 2015, 126, 739-739.	0.6	26
45	Updated Trends in Hematopoietic Cell Transplantation in the United States with an Additional Focus on Adolescent and Young Adult Transplantation Activity and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 409.e1-409.e10.	0.6	26
46	Marrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen. <i>Radiotherapy and Oncology</i> , 2016, 118, 65-71.	0.3	24
47	Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 393-399.	2.0	24
48	National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 452-466.	0.6	24
49	Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 640-645.	2.0	23
50	Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 879-883.	2.0	23
51	Human leukocyte antigen supertype matching after myeloablative hematopoietic cell transplantation with 7/8 matched unrelated donor allografts: a report from the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2016, 101, 1267-1274.	1.7	22
52	Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 270-278.	2.0	21
53	Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor. <i>Blood Advances</i> , 2020, 4, 1284-1295.	2.5	21
54	Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults. <i>Haematologica</i> , 2016, 101, 764-772.	1.7	20

#	ARTICLE	IF	CITATIONS
55	Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 599-605.	2.0	20
56	Comprehensive B Cell Phenotyping Profile for Chronic Graft-versus-Host Disease Diagnosis. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 451-458.	2.0	19
57	Proteome Profiling in Lung Injury after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1383-1390.	2.0	18
58	Broad-Spectrum Antibiotics and Risk of Graft-versus-Host Disease in Pediatric Patients Undergoing Transplantation for Acute Leukemia: Association of Carbapenem Use with the Risk of Acute Graft-versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 177.e1-177.e8.	0.6	16
59	Therapy of chronic graft-versus-host disease. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 271-279.	0.7	14
60	Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1875-1883.	2.0	14
61	Steroid-dependent acute GVHD after allogeneic hematopoietic cell transplantation: risk factors and clinical outcomes. <i>Blood Advances</i> , 2021, 5, 1352-1359.	2.5	14
62	Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigenâ€Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 421-424.	2.0	13
63	Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1776-1782.	2.0	13
64	Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. <i>Blood Advances</i> , 2018, 2, 1022-1031.	2.5	13
65	Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 34-42.	0.6	13
66	Comparison of Outcomes of Allogeneic Transplantation for Chronic Myeloid Leukemia with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan, or Total Body Irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 552-558.	2.0	12
67	GRFS and CRFS in alternative donor hematopoietic cell transplantation for pediatric patients with acute leukemia. <i>Blood Advances</i> , 2019, 3, 1441-1449.	2.5	12
68	Total Body Irradiation and Risk of Breast Cancer After Blood or Marrow Transplantation: A Blood or Marrow Transplantation Survivor Study Report. <i>Journal of Clinical Oncology</i> , 2020, 38, 2872-2882.	0.8	12
69	Outcome of Bone Marrow Transplantation for Myelofibrosis.. <i>Blood</i> , 2005, 106, 170-170.	0.6	11
70	Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report. <i>Journal of Clinical Oncology</i> , 2022, 40, 1991-2003.	0.8	11
71	Late mortality after autologous blood or marrow transplantation in childhood: a Blood or Marrow Transplant Survivor Study-2 report. <i>Blood</i> , 2018, 131, 2720-2729.	0.6	10
72	Relationship between Aging and Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1965-1970.	2.0	10

#	ARTICLE	IF	CITATIONS
73	Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1744-1755.	2.0	10
74	Use of Potentially Inappropriate Medications in Older Allogeneic Hematopoietic Cell Transplantation Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2329-2334.	2.0	10
75	Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: a BMTSS-HiGHS2 risk model. <i>Blood Advances</i> , 2021, 5, 4102-4111.	2.5	10
76	Association of CD34 cell dose with 5-year overall survival after peripheral blood allogeneic hematopoietic cell transplantation in adults with hematologic malignancies. <i>Transplantation and Cellular Therapy</i> , 2021, 28, 88-88.	0.6	10
77	Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients. <i>American Journal of Hematology</i> , 2017, 92, E529-E533.	2.0	9
78	Catheter-Related Thrombosis in Patients with Lymphoma or Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, e20-e25.	2.0	9
79	Reduced-Intensity Conditioning Followed by Related and Unrelated Allografts for Hematologic Malignancies: Expanded Analysis and Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 56-62.	2.0	9
80	Venous Thromboembolism in Autologous Blood or Marrow Transplantation Survivors: A Report from the Blood or Marrow Transplant Survivor Study. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2261-2266.	2.0	9
81	Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation. <i>Cancer</i> , 2019, 125, 4498-4508.	2.0	9
82	Late Mortality after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A Report from the Blood or Marrow Transplant Survivor Study-2 (BMTSS-2). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 328-334.	2.0	9
83	Angiogenic factors and inflammation in steroid-refractory acute graft-vs-host disease. <i>Translational Research</i> , 2016, 167, 80-87.	2.2	8
84	Design and Patient Characteristics of the Chronic Graft-versus-Host Disease Response Measures Validation Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1727-1732.	2.0	8
85	Initial therapy for chronic graft-versus-host disease: analysis of practice variation and failure-free survival. <i>Blood Advances</i> , 2021, 5, 4549-4559.	2.5	8
86	Relevance of Plasma Matrix Metalloproteinase-9 for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 759.e1-759.e8.	0.6	8
87	Phase 1 Study of Axitilimab (SNDX-6352), a CSF-1R Humanized Antibody, for Chronic Graft-Versus-Host Disease after 2 or More Lines of Systemic Treatment. <i>Blood</i> , 2020, 136, 1-2.	0.6	8
88	Fludarabine Is Superior to Cladribine When Added to Busulfan and Low Dose TBI as Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation (HCT): A Prospective Randomized Trial. <i>Blood</i> , 2004, 104, 1825-1825.	0.6	8
89	Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1485-1490.	2.0	7
90	Morbidity burden in survivors of multiple myeloma who underwent autologous transplantation: A Bone Marrow Transplantation Survivor Study. <i>Cancer</i> , 2020, 126, 3322-3329.	2.0	7

#	ARTICLE	IF	CITATIONS
91	Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 84.e1-84.e5.	0.6	7
92	Longitudinal trajectory of frailty in blood or marrow transplant survivors: Report from the Blood or Marrow Transplant Survivor Study. <i>Cancer</i> , 2021, 127, 794-800.	2.0	7
93	Outcomes of chronic graft-versus-host disease following matched sibling donor versus umbilical cord blood transplant. <i>Bone Marrow Transplantation</i> , 2021, 56, 1373-1380.	1.3	7
94	Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study. <i>Journal of Clinical Oncology</i> , 0, .	0.8	7
95	Validation Study Failed to Confirm an Association between Genetic Variants in the Base Excision Repair Pathway and Transplant-Related Mortality and Relapse after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1531-1532.	2.0	6
96	Late mortality in blood or marrow transplant survivors with venous thromboembolism: report from the Blood or Marrow Transplant Survivor Study. <i>British Journal of Haematology</i> , 2019, 186, 367-370.	1.2	6
97	Late-Onset Acute and Chronic Graft-versus-Host Disease in Children: Clinical Features and Response to Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 667.e1-667.e5.	0.6	6
98	Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. <i>Journal of Cancer</i> , 2017, 8, 1009-1017.	1.2	5
99	A cureâ€rate model for Qâ€learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients. <i>Biometrical Journal</i> , 2019, 61, 442-453.	0.6	5
100	Low 5-year health care burden after umbilical cord blood transplantation. <i>Blood Advances</i> , 2021, 5, 853-860.	2.5	5
101	Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. <i>Blood</i> , 2019, 134, 4606-4606.	0.6	5
102	A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. <i>Blood Advances</i> , 2022, 6, 259-269.	2.5	5
103	Proinflammatory Cytokine and Adipokine Levels in Adult Unrelated Marrow Donors Are Not Associated with Hematopoietic Cell Transplantation Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 12-18.	2.0	4
104	The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2468-2473.	2.0	4
105	COVID19 seroconversion in an unrelated stem cell donor. <i>Bone Marrow Transplantation</i> , 2021, 56, 723-725.	1.3	4
106	High incidence of thromboembolism in patients with chronic GVHD: association with severity of GVHD and donor-recipient ABO blood group. <i>Blood Cancer Journal</i> , 2021, 11, 96.	2.8	4
107	Impact of Frailty on Hematopoietic Cell on Early Transplant Outcomes in Older Recipients. <i>Blood</i> , 2015, 126, 388-388.	0.6	4
108	Phase 2 Results of Urinary-Derived Human Chorionic Gonadotropin/Epidermal Growth Factor As Treatment for Life-Threatening Acute Gvhd. <i>Blood</i> , 2021, 138, 261-261.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report. <i>Cancer</i> , 2019, 125, 4033-4042.	2.0	3
110	Late Mortality after Allogeneic Bone Marrow Transplantation in Childhood for Bone Marrow Failure Syndromes and Severe Aplastic Anemia. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 749-755.	2.0	3
111	New Classification of Chronic Graft Versus Host Disease: Added Clarity from the Consensus Diagnoses.. <i>Blood</i> , 2007, 110, 41-41.	0.6	3
112	Similar Survival after Umbilical Cord Blood (UCB) and HLA-Matched Adult Donor Transplantation By Disease Risk Index (DRI) Assignment. <i>Blood</i> , 2015, 126, 4375-4375.	0.6	3
113	Severe/Life-Threatening/Fatal Chronic Health Conditions (CHCs) after Allogeneic Blood or Marrow Transplantation (BMT) in Childhood - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2020, 136, 12-13.	0.6	3
114	Predictors and outcomes of flares in chronic graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	3
115	Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report. <i>Blood Advances</i> , 2022, 6, 2471-2479.	2.5	3
116	Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 509.e1-509.e11.	0.6	3
117	Late mortality after allogeneic blood or marrow transplantation in childhood for leukemia: a report from the Blood or Marrow Transplant Survivor Study-2. <i>Leukemia</i> , 2018, 32, 2706-2709.	3.3	2
118	Reduction in Late Mortality Among Patients With Multiple Myeloma Treated With Autologous Peripheral Blood Stem Cell Transplantationâ€”A Blood or Marrow Transplant Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 840.e1-840.e7.	0.6	2
119	Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study. <i>Blood</i> , 2018, 132, 71-71.	0.6	2
120	Chronic Graft Versus Host Disease (cGVHD) Following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate in Recipients of Unrelated Donor (URD) Umbilical Cord Blood (UCB).. <i>Blood</i> , 2005, 106, 1814-1814.	0.6	2
121	High Peripheral Blood Stem Cell (PBSC) CD34+ Cell Dose Increases the Risk of Chronic Gvhd after Human Leukocyte Antigen (HLA) Matched Sibling Transplantation. <i>Blood</i> , 2016, 128, 5877-5877.	0.6	2
122	Progressive Decline in Late Mortality after Hematopoietic Cell Transplantation (HCT) over 40 Years - a Report from BMTSS. <i>Blood</i> , 2016, 128, 691-691.	0.6	2
123	Pharmacogenetics of steroid-responsive acute graft-versus-host disease. <i>Clinical Transplantation</i> , 2017, 31, e12949.	0.8	1
124	Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 932-937.	1.3	1
125	Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1869-1874.	2.0	1
126	Weightâ€¢based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation. <i>European Journal of Haematology</i> , 2021, 106, 205-212.	1.1	1

#	ARTICLE	IF	CITATIONS
127	Outcomes of Grades II-IV Acute Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: How Much Progress Was Achieved?. Blood, 2015, 126, 3132-3132.	0.6	1
128	Upper Gastrointestinal Acute Graft-Versus-Host Disease Adds Minimal Prognostic Value When Present in Isolation or in Addition to Grade I or Other Grade II-Defining GvHD Manifestations. Blood, 2015, 126, 857-857.	0.6	1
129	HCT related toxicities and mortality in frail recipients.. Journal of Clinical Oncology, 2019, 37, e18534-e18534.	0.8	1
130	Association Between Genetic Variants in the Base Excision Repair Pathway and Outcomes After Hematopoietic Cell Transplant.. Blood, 2009, 114, 870-870.	0.6	1
131	Influence of Age on Risk for Acute and Chronic Graft Versus Host Disease in Children Receiving HLA Identical Sibling Bone Marrow Transplantation. Blood, 2016, 128, 2228-2228.	0.6	1
132	Burden of Long-Term Morbidity Borne By Survivors of Acute Myeloid Leukemia (AML) Treated with Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). Blood, 2019, 134, 707-707.	0.6	1
133	Stroke Risk in Blood or Marrow Transplant (BMT) Survivors - a Report from the BMT Survivor Study (BMTSS). Blood, 2019, 134, 3298-3298.	0.6	1
134	Gilbert's syndrome in haemopoietic cell transplantation. Lancet Haematology,the, 2016, 3, e500-e501.	2.2	0
135	Reduced Intensity Compared to High Dose Conditioning for Allotransplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Comparative Clinical Analysis.. Blood, 2004, 104, 1817-1817.	0.6	0
136	Acute Graft-Versus-Host Disease: Clinical Presentation and Response to Therapy Following Umbilical Cord Blood Transplant.. Blood, 2004, 104, 2148-2148.	0.6	0
137	Correlation of the NIH and Vienna Skin Scores with Provider and Patient-Reported Skin Changes in Chronic Graft-Versus-Host Disease (GVHD).. Blood, 2009, 114, 2256-2256.	0.6	0
138	Hospitalization Rates Among Long-Term Survivors of Childhood Leukemia and Lymphoma: A Report From the Childhood Cancer Survivor Study (CCSS).. Blood, 2009, 114, 4633-4633.	0.6	0
139	Gastrointestinal and Hepatic Involvement in Chronic Gvhd: An Analysis From the Chronic Gvhd Consortium. Blood, 2012, 120, 1940-1940.	0.6	0
140	Recommended Tools for Joint Chronic Graft-Versus-Host Disease: Results From the Chronic Gvhd Consortium. Blood, 2012, 120, 464-464.	0.6	0
141	Long-Term Morbidity and Mortality Experienced By Chronic Myeloid Leukemia (CML) Patients after Allogeneic Hematopoietic Cell Transplantation (HCT) - a Report from BMTSS-2. Blood, 2016, 128, 823-823.	0.6	0
142	Unrelated Male Donors Versus Sibling Parous Female Donors: Impact on Transplant-Related Outcomes. Blood, 2016, 128, 70-70.	0.6	0
143	Umbilical Cord Blood Transplantation and Delay Engraftment Are Associated with Increased Risks of Diffuse Alveolar Hemorrhage. Blood, 2016, 128, 2222-2222.	0.6	0
144	Allogeneic Hematopoietic Cell Transplantation for Elderly Patients: Prognosis Determined By Disease Risk Index. Blood, 2016, 128, 2305-2305.	0.6	0

#	ARTICLE	IF	CITATIONS
145	5 Year Health Care Burden after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Impact of Graft Source. <i>Blood</i> , 2018, 132, 367-367.	0.6	0
146	Venous Thromboembolism in Blood or Marrow Transplant (BMT) Survivors: A Report from BMT Survivor Study (BMTSS). <i>Blood</i> , 2018, 132, 823-823.	0.6	0
147	Early Broad-Spectrum Antibiotics and Risk of Acute Graft-Versus-Host Disease in Children: An Analysis from the Center for International Blood and Marrow Transplantation Research (CIBMTR) and the Pediatric Health Information System (PHIS). <i>Blood</i> , 2019, 134, 599-599.	0.6	0
148	Outcomes of Chronic Graft-Versus-Host Disease (cGVHD) Following Matched Sibling Donor (MSD) Versus Umbilical Cord Blood Transplant (UCBT). <i>Blood</i> , 2019, 134, 2009-2009.	0.6	0
149	<i>Bacterial Prophylaxis in Patients with Acute Gvhd; Who Is at Risk for Bloodstream Infections?</i> . <i>Blood</i> , 2021, 138, 2870-2870.	0.6	0
150	Low Incidence of Chronic Graft-Versus-Host Disease in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide Using Matched Related or Unrelated Donors: Phase II Study Interim Analysis. <i>Blood</i> , 2021, 138, 1811-1811.	0.6	0
151	Subsequent Malignant Neoplasms of the Gastrointestinal Tract after Blood or Marrow Transplantation - a BMTSS Report. <i>Blood</i> , 2021, 138, 3923-3923.	0.6	0
152	Trends in Late Mortality and Life Expectancy after Autologous Blood or Marrow Transplantation (BMT) Performed over Three Decades - a BMT Survivor Study (BMTSS) Report. <i>Blood</i> , 2021, 138, 484-484.	0.6	0
153	Association between Neighborhood Disadvantage and Health Status/Healthcare Utilization in Survivors of Blood or Marrow Transplantation (BMT) - a BMTSS Report. <i>Blood</i> , 2021, 138, 432-432.	0.6	0
154	Conditioning Intensity and Probability of Live Birth after Blood or Marrow Transplantation (BMT) - a Report from the BMT Survivor Study (BMTSS). <i>Blood</i> , 2021, 138, 2905-2905.	0.6	0
155	High Incidence of Venous Thromboembolism in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2020, 136, 44-46.	0.6	0
156	Predictors and Outcomes of Flares in Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
157	Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors. <i>Blood</i> , 2020, 136, 17-18.	0.6	0
158	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
159	Burden of Morbidity after Allogeneic Blood or Marrow Transplantation for Inborn Errors of Metabolism: A BMT Survivor Study Report. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 157.e1-157.e9.	0.6	0
160	Impact of CDC warning on co-prescribing of opioids and benzodiazepines in older allogeneic hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2022, , .	1.3	0